Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis
Top Cited Papers
- 17 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (14), 1439-1447
- https://doi.org/10.1093/eurheartj/ehz905
Abstract
Aims: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. We sought to characterize the structural and functional echocardiographic phenotype across the spectrum of wild-type (wtATTR-CM) and hereditary (hATTR-CM) transthyretin cardiomyopathy and the echocardiographic features predicting prognosis. Methods and results: We studied 1240 patients with ATTR-CM who underwent prospective protocolized evaluations comprising full echocardiographic assessment and survival between 2000 and 2019, comprising 766 with wtATTR-CM and 474 with hATTR-CM, of whom 314 had the V122I variant and 127 the T60A variant. At diagnosis, patients with V122I-hATTR-CM had the most severe degree of systolic and diastolic dysfunction across all echocardiographic parameters and patients with T60AhATTR-CM the least; patients with wtATTR-CM had intermediate features. Stroke volume index, right atrial area index, longitudinal strain, and E/e’ were all independently associated with mortality (P < 0.05 for all). Severe aortic stenosis (AS) was also independently associated with prognosis, conferring a significantly shorter survival (median survival 22 vs. 53 months, P = 0.001). Conclusion: The three distinct genotypes present with varying degrees of severity. Echocardiography indicates a complex pathophysiology in which both systolic and diastolic function are independently associated with mortality. The presence of severe AS was independently associated with significantly reduced patient survival.Keywords
Funding Information
- British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/21/33447)
This publication has 26 references indexed in Scilit:
- Diagnosis, Prognosis, and Therapy of Transthyretin AmyloidosisJournal of Invasive Cardiology, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEuropean Heart Journal, 2015
- Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear CardiologyThe American Journal of Medicine, 2015
- The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosisAmyloid, 2014
- 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathyEuropean Heart Journal, 2014
- Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac AmyloidosisCirculation, 2014
- Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)American Heart Journal, 2012
- Frequency and distribution of senile cardiovascular amyloid: A clinicopathologic correlationThe American Journal of Medicine, 1983